BridgeBio Pharma
BBIO
BBIO
253 hedge funds and large institutions have $4.39B invested in BridgeBio Pharma in 2024 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 107 increasing their positions, 74 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
1% more funds holding
Funds holding: 251 → 253 (+2)
1% less capital invested
Capital invested by funds: $4.43B → $4.39B (-$38.7M)
1.72% less ownership
Funds ownership: 93.5% → 91.78% (-1.7%)
Holders
253
Holding in Top 10
13
Calls
$288M
Puts
$68.9M
Top Buyers
| 1 | +$45.9M | |
| 2 | +$27.3M | |
| 3 | +$21.1M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$20.6M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$13.3M |
Top Sellers
| 1 | -$152M | |
| 2 | -$36.8M | |
| 3 | -$30.8M | |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$27.6M |
| 5 |
Man Group
London,
United Kingdom
|
-$15.7M |